SCHEMBL336010

SCHEMBL336010

COc1cc(C(C)NCCN)cc(OC)c1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.35
POLB P06746 1/20 0.35
GPR183 P32249 1/20 0.32
BCDIN3D Q7Z5W3 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HTR2B P41595 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.31
ATM Q13315 1/20 0.31
NFKB1 P19838 1/20 0.31
CYP1A2 P05177 1/20 0.30
HSP90AA1 P07900 1/20 0.30
HSP90AB1 P08238 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30
DHFR P00374 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24538503 0.74 HTR2A (0.62) NPSR1POLBHTR2AHTR2CHTR2B
SCHEMBL31706762 0.71 POLB (0.40) NPSR1POLBMAPTATMDHFR
SCHEMBL19354644 0.70 CRHR1 (0.40) NPSR1POLBHTR2AHTR2CMEN1
SCHEMBL335431 0.69 NFKB1 (0.57) NPSR1LMNANFKB1BLMPMP22
SCHEMBL20777142 0.68 AKR1C3 (0.44) NPSR1POLBMEN1KMT2ATDP1
SCHEMBL31706038 0.68 NPSR1 (0.39) NPSR1POLBMEN1KMT2AMAPT
SCHEMBL13137647 0.68 MAPK1 (0.45) GPR183HTR2AMEN1KMT2AMAPT
SCHEMBL26292815 0.67 NPSR1 (0.38) NPSR1POLBMAPTATMDHFR
SCHEMBL38657495 0.67 NPSR1 (0.36) NPSR1POLBHTR2AHTR2CHTR2B
SCHEMBL29170715 0.67 HTR2A (0.55) NPSR1POLBHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 NPSR1 2990/4885POLB 3348/4885GPR183 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.